SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Castel D)
 

Sökning: WFRF:(Castel D) > Diffuse intrinsic p...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006701naa a2200565 4500
001oai:DiVA.org:uu-348978
003SwePub
008180426s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3489782 URI
0247 a https://doi.org/10.1007/s11060-017-2702-72 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Lobon-Iglesias, M. J.u Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.4 aut
2451 0a Diffuse intrinsic pontine gliomas (DIPG) at recurrence :b is there a window to test new therapies in some patients?
264 c 2017-12-02
264 1b SPRINGER,c 2018
338 a print2 rdacarrier
520 a Children with diffuse intrinsic pontine glioma (DIPG) need new and more efficient treatments. They can be developed at relapse or at diagnosis, but therefore they must be combined with radiotherapy. Survival of children after recurrence and its predictors were studied to inform the possibility to design early phase clinical trials for DIPG at this stage. Among 142 DIPG patients treated between 1998 and 2014, 114 had biopsy-proven DIPG with histone H3 status available for 83. We defined as long survivors' patients who survived more than 3 months after relapse which corresponds to the minimal life expectancy requested for phase I/II trials. Factors influencing post-relapse survival were accordingly compared between short and long-term survivors after relapse. Fifty-seven percent of patients were considered long survivors and 70% of them had a Lansky Play Scale (LPS) above 50% at relapse. Patients who became steroids-independent after initial treatment for at least 2 months had better survival after relapse (3.7 versus 2.6 months, p = 0.001). LPS above 50% at relapse was correlated with better survival after relapse (3.8 versus 1.8 months, p < 0.001). Patients with H3.1 mutation survived longer after relapse (4.9 versus 2.7 months, p = 0.007). Patients who received a second radiotherapy at the time of relapse had an improved survival (7.5 versus 4 months, p = 0.001). In the two-way ANOVA analysis, steroid-independence and LPS predicted survival best and the type of histone H3 (H3.1 or H3.3) mutated did not improve prediction. Survival of many DIPG patients after relapse over 3 months would make possible to propose specific trials for this condition. Steroid-independence, H3 mutation status and LPS should be considered to predict eligibility.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Brainstem glioma
653 a H3K27M mutation
653 a Midline infiltrative glioma
653 a Steroid-independence
7001 a Giraud, Geraldineu Uppsala universitet,Science for Life Laboratory, SciLifeLab,Neuroonkologi,Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France4 aut0 (Swepub:uu)gergi266
7001 a Castel, D.u Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.4 aut
7001 a Philippe, C.u Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.4 aut
7001 a Debily, M. A.u Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.;Univ Evry Val dEssone, Evry, France.4 aut
7001 a Briandet, C.u Univ Hosp Dijon, Dept Pediat, Dijon, France.4 aut
7001 a Fouyssac, F.u Univ Hosp Nancy Brabois, Dept Pediat Oncol, Nancy, France.4 aut
7001 a de Carli, E.u Univ Hosp Angers, Dept Pediat Oncol, Angers, France.4 aut
7001 a Dufour, C.u Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.4 aut
7001 a Valteau-Couanet, D.u Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.4 aut
7001 a Sainte-Rose, C.u Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.4 aut
7001 a Blauwblomme, T.u Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.4 aut
7001 a Beccaria, K.u Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.;Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.4 aut
7001 a Zerah, M.u Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.4 aut
7001 a Puget, S.u Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.4 aut
7001 a Calmon, R.u Paris Descartes Univ, Paris, France.;Necker Sick Childrens Univ Hosp, Dept Radiol, Paris, France.;Imagine Inst, Paris, France.;INSERM, U1163, Paris, France.4 aut
7001 a Boddaert, N.u Paris Descartes Univ, Paris, France.;Necker Sick Childrens Univ Hosp, Dept Radiol, Paris, France.;Imagine Inst, Paris, France.;INSERM, U1163, Paris, France.4 aut
7001 a Bolle, S.u Gustave Roussy, Dept Radiotherapy, Villejuif, France.4 aut
7001 a Varlet, P.u Paris Descartes Univ, Paris, France.;St Anne Hosp, Dept Neuropathol, Paris, France.4 aut
7001 a Grill, J.u Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.4 aut
7102 a Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.b Science for Life Laboratory, SciLifeLab4 org
7730 t Journal of Neuro-Oncologyd : SPRINGERg 137:1, s. 111-118q 137:1<111-118x 0167-594Xx 1573-7373
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-348978
8564 8u https://doi.org/10.1007/s11060-017-2702-7

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy